Glucagon-like peptide 1 therapy: from discovery to type 2 diabetes and beyond
It possesses in vitro balanced GIPR (EC50 = 3 pM) and GLP-1R (EC50 = 5 pM) agonism with relative activity seven times that of GIP to GIPR and five times that of GLP-1 to GLP-1R, respectively (44)
Concerns also exist about weight regain after discontinuing the medication
The researchers also conducted a prespecified subgroup analysis of patients who underwent upper endoscopy alone (n = 35) or with colonoscopy (n = 25)
Nevertheless, numerous ongoing trials are investigating the cardiometabolic effects of GLP-1RAs in patients with mental illness, especially for those on antipsychotics (Supplementary Section 3)such research should therefore address the abovementioned knowledge gap
In addition, exenatide was shown to activate GLP-1R and inhibit the PI3K/AKT pathway to inhibit the growth, migration, and invasion of ovarian cancer cells, and promote cell apoptosis, thereby producing anticancer effects on diabetic patients with ovarian cancer (218)
